A randomised controlled trial investigating the effect of an intensive lifestyle intervention v. standard care in adults with type 2 diabetes immediately after initiating insulin therapy

British Journal of Nutrition

Volumn 99, Issue 5, 2008, Pages 1025-1031

  Barratt, Rachel ^a,b   Frost, Gary ^a,c   Millward, D J ^a   Truby, Helen ^d  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Insulin therapy; Obesity; Type 2 diabetes; Weight loss

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LIPID;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; DIABETES MELLITUS, TYPE 2; DIETETICS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIFE STYLE; LIPIDS; MIDDLE AGED; OBESITY; PATIENT EDUCATION AS TOPIC; WEIGHT GAIN; YOUNG ADULT;

EID: 53049095513     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114507839018     Document Type: Article

References (24)

1. Astrup A & Finer N (2000) Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev 1, 57-59.
2. World Health Organization (2006) Global strategy on diet, physical activity and health: Diabetes http://www.who.int/dietphysicalactivity/ publications/facts/diabetes/en/index.html
3. Lipscombe LL & Hux JE (2007) Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: A population-based study. Lancet 369, 750-756.
4. United Kingdom Prospective Diabetes Study Group (1995) Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years (UKPDS 13). BMJ 310, 83-88.
5. Turner R, Cull C & Holman R (1996) United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124, 136-145.
6. United Kingdom Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853.
7. Davidson MH, Hauptman J, DiGirolamo M, et al. (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with Orlistat: A randomized controlled trial. JAMA 281, 235-242.
8. Dickinson PJ, Dornhorst A & Frost GS (2002) A retrospective case-control study of initiating insulin therapy in type 2 diabetes. Pract Diabetes Int 19, 67-70.
9. Khan R (2004) Weight gain and insulin therapy. Br J Diabetes Vasc Dis 4, 264-267.
10. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE & Hennekens CH (1995) Weight, weight change and coronary heart disease in women. JAMA 273, 461-465.
11. Wannameethee G & Shaper AG (1990) Weight change in middle-aged British men: Implications for health. Eur J Clin Nutr 44, 133-142.
12. Garrow JS (1995) Penalties of shifting weight. BMJ 311, 1653-1654.
13. Davies M (2004) The reality of glycaemic control in insulin treated diabetes: Defining the clinical challenges. Int J Obes Relat Metab Disord 28, Suppl. 2, S14-S22.
14. Frost G, Lyons F, Bovill-Taylor C, Carter L, Stuttard J & Dornhorst A (2002) Intensive lifestyle intervention combined with the choice of pharmacotherapy improves weight loss and cardiac risk factors in the obese. J Hum Nutr Diet 15, 287-295.
15. Diabetes Prevention Program (DPP) Research Group (2002) The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care 25, 2165-2171.
16. Stevens RJ, Kothari V, Adler AI & Stratton JM (2001) The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 101, 671-679.
17. International Diabetes Federation (2005) The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels: International Diabetes Federation.
18. Guzder RN, Gatling W, Mullee MA, Mehta RL & Byrne CD (2005) Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes; results from a UK study. Diabetes Med 22, 554-562.
19. Ash S, Reeves MM, Yeo S, Morrison G, Carey D & Capra S (2003) Effect of intensive dietetic interventions on weight and glycaemic control in overweight men with type II diabetes: A randomised trial. Int J Obes Relat Metab Disord 27, 797-802.
20. Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, Nathan D & Vinicor FAmerican Diabetes Association (2003) Implications of the United Kingdom prospective diabetes study. Diabetes Care 26, Suppl. 1, S28-S32.
21. Klein R (1995) Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18, 258-268.
22. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR & Golden SH (2004) Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 421-431.
23. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329, 977-986.
24. Phillips A (2007) Experiences of patients with type 2 diabetes starting insulin therapy. Nurs Stand 21, 35-41.